Drug Database
Back to search

Sweden· SE-20210503000054

Copneg 0,5 mg/ml + 2,5 mg/ml Injektionsvätska, lösning

A medicinal product containing glycopyrronium bromide + neostigmine metilsulfate, registered in Sweden by EQL Pharma AB.

Checked against Swedish Medical Products Agency (Sweden) on

Informational only — not a medical device.

SOURCE REGISTER · SESwedish Medical Products Agency (Sweden)normalisedCopneg 0,5 mg/ml + 2,5 mg/ml Injektio…ATC—REGISTER NO.SE-20210503000054PACKS LISTED1CHECKEDOctober 1, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about glycopyrronium bromide + neostigmine metilsulfateAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

The record

At a glance

Swedish Medical Products Agency (Sweden)
Active substance
Glycopyrronium Bromide + Neostigmine Metilsulfate
Manufacturer
EQL Pharma AB
Country
Sweden (SE)
ATC code
—
Reimbursed
Not published by this register
Source register
Swedish Medical Products Agency (Sweden)
Last checked
October 1, 2026

Packs & prices · 1

  • se_varunummer
    20210503000054

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Glycopyrronium bromide + neostigmine metilsulfate in 4 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All glycopyrronium bromide + neostigmine metilsulfate products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Austria · Combistig
  • Belgium · Robinul-Neostigmine
  • Denmark · Copneg, Robinul-Neostigmin
  • Estonia · Glynex
  • Finland · Copneg, Glycostigmin
  • United Kingdom (Northern Ireland) · Glycopyrrolate And Neostigmine Metilsulfate Mercury Pharmaceuticals Ltd,, Glycopyrronium Bromide And Neostigmine Metilsulfate Martindale Pharmaceuticals
  • Croatia · Novistig
  • Hungary · Novistig
  • Ireland · Glycopyrronium Bromide And Neostigmine Metilsulfate Mercurypharm, Novistig
  • Luxembourg · Robinul-Neostigmine
  • Norway · Copneg, Robinul-Neostigmin
  • Poland · Novistig
  • Slovenia · Novistig

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/620b64a0-9ad8-4742-9762-e250561748a2
GET /v1/drugs/620b64a0-9ad8-4742-9762-e250561748a2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "source": "lakemedelsverket",
  "doc_types": [
    "SmPC",
    "PL"
  ],
  "se_npl_id": "20210503000054",
  "product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20210503000054",
  "product_doc_link": "https://docetp.mpa.se/LMF/Copneg%200.5%20mg%20per%20ml_2.5%20mg%20per%20ml%2C%20solution%20for%20injection%20SmPC_09001bee8324180e.pdf"
}
API referenceMCP serverPlans

See everything about glycopyrronium bromide + neostigmine metilsulfate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console